P Glue

Summary

Affiliation: Schering-Plough Research Institute
Country: USA

Publications

  1. pmc The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease
    P Glue
    Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Br J Clin Pharmacol 49:417-21. 2000
  2. ncbi request reprint A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group
    P Glue
    Schering Plough Research Institute, Kenilworth, NJ
    Hepatology 32:647-53. 2000
  3. ncbi request reprint Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C
    J F Jen
    Department of Statistics, Schering Plough Research Institute, Kenilworth, NJ 007033, USA
    Clin Pharmacol Ther 69:407-21. 2001
  4. ncbi request reprint Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment
    S K Gupta
    Departments of Drug Metabolism Pharmacokinetics and Clinical Pharmacology, Merck Research Lab, Kenilworth, NJ, USA
    Drug Discov Ther 7:158-63. 2013

Collaborators

Detail Information

Publications4

  1. pmc The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease
    P Glue
    Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Br J Clin Pharmacol 49:417-21. 2000
    ..Additionally this study assessed the safety and tolerability of ribavirin in this population...
  2. ncbi request reprint A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group
    P Glue
    Schering Plough Research Institute, Kenilworth, NJ
    Hepatology 32:647-53. 2000
    ..Combined PEG-Intron/ribavirin showed dose-related synergistic anti-HCV effects, which were numerically superior to those obtained with PEG-Intron monotherapy...
  3. ncbi request reprint Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C
    J F Jen
    Department of Statistics, Schering Plough Research Institute, Kenilworth, NJ 007033, USA
    Clin Pharmacol Ther 69:407-21. 2001
    ..Possible relationships between pharmacokinetic and pharmacodynamic variables were investigated...
  4. ncbi request reprint Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment
    S K Gupta
    Departments of Drug Metabolism Pharmacokinetics and Clinical Pharmacology, Merck Research Lab, Kenilworth, NJ, USA
    Drug Discov Ther 7:158-63. 2013
    ..The pharmacokinetics of ribavirin were substantially altered in subjects with stable chronic renal impairment, possibly reflecting changes in ribavirin metabolism associated with renal impairment. ..